A detailed history of Pro Share Advisors LLC transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 69,995 shares of SMMT stock, worth $527,762. This represents 0.0% of its overall portfolio holdings.

Number of Shares
69,995
Previous 63,960 9.44%
Holding current value
$527,762
Previous $166,000 74.1%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

BUY
$2.55 - $5.07 $15,389 - $30,597
6,035 Added 9.44%
69,995 $289,000
Q4 2023

Feb 14, 2024

BUY
$1.67 - $2.83 $5,502 - $9,324
3,295 Added 5.43%
63,960 $166,000
Q3 2023

Nov 13, 2023

BUY
$1.54 - $2.42 $694 - $1,091
451 Added 0.75%
60,665 $113,000
Q2 2023

Aug 10, 2023

BUY
$1.32 - $2.81 $15,634 - $33,281
11,844 Added 24.49%
60,214 $151,000
Q1 2023

May 11, 2023

BUY
$1.38 - $5.41 $43,772 - $171,599
31,719 Added 190.49%
48,370 $84,000
Q4 2022

Feb 02, 2023

SELL
$0.68 - $5.31 $186 - $1,454
-274 Reduced 1.62%
16,651 $70,000
Q3 2022

Nov 04, 2022

BUY
$0.89 - $1.63 $15,063 - $27,587
16,925 New
16,925 $20,000
Q2 2022

Aug 01, 2022

SELL
$0.92 - $2.38 $13,849 - $35,828
-15,054 Closed
0 $0
Q1 2022

May 10, 2022

SELL
$2.0 - $3.45 $8,928 - $15,400
-4,464 Reduced 22.87%
15,054 $37,000
Q4 2021

Feb 08, 2022

SELL
$2.45 - $5.64 $11,424 - $26,299
-4,663 Reduced 19.28%
19,518 $52,000
Q3 2021

Nov 12, 2021

BUY
$4.83 - $8.27 $4,235 - $7,252
877 Added 3.76%
24,181 $121,000
Q2 2021

Aug 13, 2021

BUY
$5.15 - $8.46 $61,176 - $100,496
11,879 Added 103.97%
23,304 $174,000
Q1 2021

May 14, 2021

SELL
$5.17 - $11.19 $6,571 - $14,222
-1,271 Reduced 10.01%
11,425 $67,000
Q4 2020

Feb 09, 2021

BUY
$3.25 - $6.0 $41,262 - $76,176
12,696 New
12,696 $60,000

Others Institutions Holding SMMT

About Summit Therapeutics Inc.


  • Ticker SMMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 201,215,008
  • Market Cap $1.52B
  • Description
  • Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...
More about SMMT
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.